Morrissey, Kari M.
Stocker, Sophie L.
Chen, Eugene C.
Castro, Richard A.
Brett, Claire M.
Giacomini, Kathleen M.
Funding for this research was provided by:
NIH/NCRR (UL1 RR024131)
National Institutes of Health (GM61390, T32 GM007175, T32 GM007175)
Allergan
FDA-CDER/ORISE
Article History
First Online: 27 October 2015
Compliance with Ethical Standards
:
: This project was supported by National Institutes of Health/National Center for Research Resources (NIH/NCRR) University of California, San Francisco (UCSF)-Clinical & Translational Science Institute (CTSI) Grant UL1 RR024131 & NIH Grant GM61390. The authors are solely responsible for the contents and do not necessarily represent the official views of the NIH. This work was also made possible in part by core services provided by the General Clinical Research Center (GCRC) at San Francisco General Hospital (SFGH), funded by the NCRR (NIH MO1-RR00083-44). The authors also acknowledge the following funding sources for SLS. (Allergan) and ECC and KMM (NIH Training Grant T32 GM007175, FDA-CDER/ORISE).
: The authors have no conflicts of interest that might be relevant to the content of this manuscript.
: The Committee on Human Research at the University of California, San Francisco (Institutional Review Board [IRB] 11-06968) approved the clinical drug–drug interaction study, and all subjects were recruited directly from the Study of Pharmacogenetics in Ethnically Diverse Populations (IRB 10-03167). Informed consent was obtained from all study participants.